On December 16, Glonghui reported that Bio-Thera Solutions (688177.SH) announced the convening of the 20th meeting of the 2nd Board of Directors on December 16, 2024, to review and approve the proposal regarding the signing of the licensing and production, supply, and commercialization agreement with SteinCares for BAT2306 (Tucatinib injection). The company signed a licensing and commercialization agreement with Stein on March 18, 2024, granting exclusive commercialization rights for BAT2506 (Golimumab injection) and BAT2606 (Mepolizumab injection) in Brazil and the remaining Latin American markets to Stein, for which it can receive a total payment of up to 6 million USD, including a 1.2 million USD upfront payment, cumulative milestone payments of no more than 4.8 million USD, and a double-digit percentage of net sales as revenue sharing.